8-K: Capricor Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics reported its third quarter 2024 financial results, initiated a rolling BLA submission for deramiocel, and announced a European expansion agreement with Nippon Shinyaku.

Summary

• Capricor Therapeutics announced its financial results for the third quarter ended September 30, 2024.
• The company initiated a rolling Biologics License Application (BLA) submission for deramiocel to treat all patients with DMD-cardiomyopathy, with full submission expected by the end of 2024.
• A potential PDUFA date is anticipated in the second half of 2025.
• Capricor signed a binding term sheet with Nippon Shinyaku for European expansion and commercialization of deramiocel, potentially totaling $1.5 billion in milestones.
• Positive long-term data from the HOPE-2 OLE trial was presented at the 2024 World Muscle Society Congress.
• The StealthX exosome platform was expanded to include PMO loading and targeting for DMD treatment.
• A public offering of common stock was completed, raising approximately $86 million, extending the cash runway into 2027.
• Third quarter revenue was $2.3 million, compared to $6.2 million in the same quarter of 2023.
• The company reported a net loss of $12.6 million, or $0.38 per share, for the third quarter of 2024, compared to a net loss of $6.4 million, or $0.25 per share, for the third quarter of 2023.
• Cash, cash equivalents, and marketable securities totaled approximately $85 million as of September 30, 2024, compared to $39.5 million as of December 31, 2023.

Sentiment

Score: 7

Explanation: The document presents a mix of positive developments, such as the BLA submission and the Nippon Shinyaku deal, and negative financial results, including increased losses. The overall sentiment is cautiously optimistic due to the potential for future growth and commercialization.

Positives

• The initiation of the BLA submission for deramiocel is a significant step towards potential commercialization.
• The European expansion agreement with Nippon Shinyaku provides a substantial opportunity for revenue growth.
• The successful public offering has significantly strengthened the company's financial position.
• Positive long-term data from the HOPE-2 OLE trial supports the efficacy of deramiocel.
• The expansion of the StealthX platform demonstrates innovation in targeted therapeutics.
• The company's cash runway extends into 2027, providing financial stability.

Negatives

• Third quarter revenue decreased to $2.3 million from $6.2 million in the same quarter of the previous year.
• The company reported a net loss of $12.6 million for the third quarter of 2024, compared to a net loss of $6.4 million for the same period in 2023.
• Operating expenses increased to $15.3 million in the third quarter of 2024, compared to $13.1 million in the third quarter of 2023.

Risks

• The BLA submission is subject to FDA review and approval, which is not guaranteed.
• The European expansion agreement with Nippon Shinyaku is subject to finalization of a definitive agreement.
• The company's financial performance is dependent on the success of its product candidates and partnerships.
• The company is still incurring significant losses and is reliant on future funding.
• The clinical trial for the StealthX vaccine is subject to NIAID's approval and funding.

Future Outlook

The company believes its current cash resources will be sufficient to cover anticipated expenses and capital requirements into 2027, excluding potential milestone payments and strategic capital use.

Management Comments

• This has been a transformational quarter for Capricor as we move towards potential commercialization of deramiocel for the treatment of DMD, said Linda Marbn, Ph.D., Capricor's chief executive officer.
• We have commenced the submission of our BLA which we expect to be complete by year end and we have significantly strengthened our balance sheet in order to scale up manufacturing as we anticipate a strong launch, pending FDA approval.
• We continue to explore partnership opportunities and other non-dilutive sources of funding to advance this program.

Industry Context

The announcement reflects the ongoing efforts in the biotechnology sector to develop treatments for rare diseases, particularly Duchenne muscular dystrophy, and highlights the importance of strategic partnerships and financial stability for companies in this space.

Comparison to Industry Standards

• Capricor's progress with deramiocel is comparable to other companies developing cell therapies for DMD, such as Sarepta Therapeutics and Solid Biosciences, though Capricor is focused on cardiac aspects.
• The $1.5 billion potential milestone payments from the Nippon Shinyaku deal are significant and demonstrate the potential value of deramiocel, similar to other large biotech deals in the rare disease space.
• The company's cash runway into 2027 is a positive sign, as many biotech companies face funding challenges, and this is comparable to companies that have recently completed successful capital raises.
• The expansion of the StealthX platform is in line with the industry trend of exploring exosome-based therapies, with companies like Codiak BioSciences and Evox Therapeutics also working in this area.

Related Party Transactions

• Capricor has an agreement with Nippon Shinyaku for the commercialization and distribution of deramiocel in the United States and Japan.
• Nippon Shinyaku purchased approximately $15 million of Capricor common stock at a 20% premium.

Stakeholder Impact

• Shareholders will be impacted by the increased cash position and potential future revenue from the Nippon Shinyaku deal.
• Employees may benefit from the company's growth and expansion.
• Patients with DMD may benefit from the potential approval of deramiocel.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Complete the full BLA submission for deramiocel by the end of 2024.
• Finalize the definitive agreement with Nippon Shinyaku for European expansion.
• Continue to advance the StealthX exosome platform.
• Deliver the StealthX vaccine to NIAID in the first quarter of 2025.
• Present at upcoming industry conferences.
• Work with regional health authorities for regulatory approval of deramiocel in Europe and Japan.

Key Dates

Keywords

deramiocel, DMD, StealthX, exosomes, BLA, Nippon Shinyaku, clinical trial, biotechnology, cell therapy, rare diseases, financial results, public offering